BEAM Alliance

Driving Innovation, Shaping Policy:
Europe’s SMEs United Against AMR

BEAM at work

Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.

PULL incentives
PUSH incentives
Diagnostics
Prevention

Evaluation
Phages
National actions
BEAM papers

Members

Latest news

28 May 2026

Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam

Basilea is proud to be developing ceftibuten-ledaborbactam in partnership with BARDA. This funding helps us to further advance this novel…

22 April 2026

BioVersys completes BV100 Phase 1 clinical trial in China

The completion of this mandatory Phase 1 safety and pharmacokinetic clinical trial in China is crucial in the development of…

21 April 2026

Integrating Biodefence into the European Competitiveness Fund: A Strategic Imperative

This new paper highlights the urgent need to recognise antimicrobial resistance (AMR) as both a public health threat and a security…

All the news

Legal notice | Photo credits

Who we are
Overview
Members
Pipeline
News

Connect with us

contact@beam-alliance.eu
29 Avenue Tony Garnier 69007 Lyon - France